APPLICATION FOR TREATING AND PREVENTING ATHEROSCLEROSIS OF PROTEIN-PEPTIDE COMPLEX (HEREINAFTER PPC) OBTAINED FROM EMBRYONIC NERVE TISSUE OR OF QUICK FROZEN EMBRYO BRAIN OF FARM HOOFED ANIMALS AFFECTING CHECK TRANSPORT CHOLESTEROL FROM VASCULAR WALL AND PROFILE OF ACTIVATION OF MONOCYTES IN PATIENTS WITH MANIFESTED ATHEROSCLEROSIS OF GREAT VESSELS OR WITH PREDISPOSITION TO CARDIOVASCULAR DISEASES AND METHOD FOR PREVENTING AND TREATING PATIENTS WITH ARTERIAL ATHEROSCLEROSIS AND DISEASES CAUSED BY ATHEROSCLEROSIS OF MAJOR AND PERIPHERAL VASCULAR CEREBRAL, HEART, AORTA AND LOWER EXTREMITIES (TWO VERSIONS)

摘要

FIELD: medicine.;SUBSTANCE: group of inventions relates to medicine,specifically to therapy, and can be used for treatment of atherosclerosis of aorta and great vessels using a pharmaceutical agent comprising a protein-peptide therapeutic agent (BPK). BPK is derived from embryonic neural tissue or quick-frozen in foetal brain of agricultural ungulates. BPK includes neutral, negatively charged proteins and polypeptides with molecular weights of 0.5 to 200 kDa or in combination thereof with polynucleotides in form of Na salts of DNA isolated from sturgeon milt or salmon. BPK is administered in a therapeutically effective daily dosage and course parenterally or intranasally. Group of inventions relates to use of BBK with total concentration of protein 0.05-4.2 mg/ml, which determines its biological activity, with molecular weight of 0.5 to 200 kDa, wherein at least 70 % of total weight of protein has a molecular weight from 20 to 160 kDa, having a specific set of characteristic bands in denaturing gel electrophoresis in 5 % polyacrylamide gel electrophoresis, isoelectric point value of 4.2 to 8.4 and an absorption maximum at a wavelength of 215±5 nm for removing ultraviolet spectrum in wavelength range from 200 to 500 nm.;EFFECT: use of present group of inventions allows use of BPK in prevention and treatment of patients with atherosclerosis, ensuring an impact on reverse transport of cholesterol from vessel wall and profile of activation of monocytes in patients and regulating metabolism of cholesterol, cholesterol esters, triglycerides, phospholipids subendothelial connective tissue and smooth muscle cells of arterial vessels.;29 cl, 5 tbl, 8 ex